Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The government have already stated that they won’t even contemplate rolling this out without accuracy, so the consortium are well aware of this. I would say going by this mornings interview they’re very confident. As does the market...
They wouldn’t ramp it up if it wasn’t going to meet government standards
With out competitive accuracy figures they won't get the sales, whilst they may have set up huge production capacity its no good if people don't want the product.
Without news on accuracy or PHE approval the price will drift down
Here is some data on the accuracy of other tests, https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance
The Positive Predictive values for other lateral flow tests are really bad around the 50% mark. Other lab tests go as high as 100%. ODX need to release their figures ASAP
If they test everyone in UK that be 660m revenue, each person will need more than one test . As immunity might different in the individual.
That's just UK the world is a big place .
All in good time, this will be very accurate over 99% easily hence the production uplift and recruitment policy. Game on here...
That's the elephant in the room PadRock... Looking at this price jump that looks ok! Fingers crossed!
Just looked through the various announcements and stories and there is no mention of accuracy, this is a little worrying. Lots of other companies have struggled to achieve high accuracy with at home kits. Surely if this kit was better they'd be shouting the figures from the rooftops?
Surely anything that gives a result is competition, its just that there's been a lot of negative press about at home tests with low accuracy. Have ODX released figures like the other companies?
What's the performance of this test like? The competition have 100% sensitivity (ability to detect COVID-19 antibodies) and 99.8% specificity (ability to rule out the presence of COVID-19 antibodies), although they are more than 10 times the price